<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30680" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tumor Lysis Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Adeyinka</surname>
            <given-names>Adebayo</given-names>
          </name>
          <aff>The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaur</surname>
            <given-names>Anahat</given-names>
          </name>
          <aff>Charleston Area Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bashir</surname>
            <given-names>Khalid</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adebayo Adeyinka declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anahat Kaur declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khalid Bashir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30680.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Tumor lysis syndrome is a critical medical condition that arises from the rapid breakdown of tumor cells, leading to significant metabolic disturbances such as hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. These&#x000a0;disturbances can result in severe complications, including acute kidney injury, cardiac arrhythmias, and even death. Tumor lysis syndrome is commonly observed in patients undergoing treatment for hematologic malignancies such as non-Hodgkin lymphomas, acute leukemias, and Burkitt lymphoma, particularly following the initiation of chemotherapy. However, tumor lysis syndrome may also occur spontaneously.</p>
        <p>Patients at high risk of developing tumor lysis syndrome typically have neoplasms with a high proliferative rate and significant sensitivity to chemotherapy. Prevention and early intervention are crucial. Strategies include aggressive hydration; the use of hypouricemic agents, such as allopurinol or rasburicase; and close monitoring of metabolic parameters. Timely recognition and management of tumor lysis syndrome are essential to reducing patient morbidity, emphasizing the importance of vigilant monitoring during cancer treatment.&#x000a0;This activity reviews the epidemiology, pathophysiology, identification, evaluation, and management of tumor lysis syndrome, highlighting the role of the interprofessional team in improving outcomes for patients with this life-threatening disease condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at risk for developing tumor lysis syndrome based on their clinical history.</p></list-item><list-item><p>Select interventions for patients with tumor lysis syndrome to prevent or mitigate end-organ injury and failure.</p></list-item><list-item><p>Apply best practices to reduce the incidence of tumor lysis syndrome in high-risk patients.</p></list-item><list-item><p>Implement interprofessional team strategies to improve care coordination and outcomes in&#x000a0;patients with tumor lysis syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30680&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30680">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30680.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Tumor lysis syndrome is a clinical condition caused by extensive tumor cell lysis and characterized by metabolic disturbances, such as hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia, which can lead to end-organ damage. This syndrome is most commonly observed in patients with hematologic malignancies.<xref ref-type="bibr" rid="article-30680.r1">[1]</xref><xref ref-type="bibr" rid="article-30680.r2">[2]</xref><xref ref-type="bibr" rid="article-30680.r3">[3]</xref> Tumor lysis syndrome is a significant metabolic and oncologic emergency commonly encountered in clinical practice. This condition can occur in both adult and pediatric oncology patients undergoing chemotherapy. The symptoms of tumor lysis syndrome primarily result from the release of intracellular substances, including potassium, phosphates, and nucleic acids, into the circulation. This release impairs the function of target organs and can lead to acute kidney injury, life-threatening arrhythmias, and potentially death.</p>
        <p>Tumor lysis syndrome typically arises following the initiation of chemotherapy, although it can also occur spontaneously in cases of high-grade hematologic malignancies characterized by substantial tumor burdens. Given the severe lethality of tumor lysis syndrome, identifying patients at increased risk and initiating early preventive measures are crucial. Prompt recognition of the renal and metabolic disturbances associated with tumor lysis syndrome&#x000a0;and timely initiation of treatment&#x000a0;are essential for improving patient survival.<xref ref-type="bibr" rid="article-30680.r4">[4]</xref><xref ref-type="bibr" rid="article-30680.r5">[5]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30680.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The risk of tumor lysis syndrome is the highest in patients undergoing treatment for hematologic malignancies. Tumors most commonly associated with tumor lysis syndrome include clinically aggressive non-Hodgkin lymphomas, acute lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma&#x000a0;or Burkitt&#x000a0;leukemia. These tumors have a high proliferative rate and demonstrate significant sensitivity to chemotherapy.<xref ref-type="bibr" rid="article-30680.r6">[6]</xref> Other hematologic malignancies are less commonly associated with tumor lysis syndrome.</p>
        <p>Solid tumors that can cause tumor lysis syndrome are small cell carcinoma of the lung, breast cancer, and neuroblastoma.<xref ref-type="bibr" rid="article-30680.r7">[7]</xref><xref ref-type="bibr" rid="article-30680.r8">[8]</xref><xref ref-type="bibr" rid="article-30680.r9">[9]</xref><xref ref-type="bibr" rid="article-30680.r10">[10]</xref>&#x000a0;International panels of experts have stratified tumors based on the risk of developing tumor lysis syndrome.<xref ref-type="bibr" rid="article-30680.r11">[11]</xref><xref ref-type="bibr" rid="article-30680.r12">[12]</xref>&#x000a0;Patients are generally categorized into 3 risk levels&#x02014;high risk, where greater than 5% of patients develop tumor lysis syndrome; intermediate risk, with 1% to 5% of patients developing tumor lysis syndrome; and low risk, with fewer than 1% of patients developing tumor lysis syndrome. The tumors associated with each risk category include:</p>
        <list list-type="bullet">
          <list-item>
            <p>High-risk tumors
<list list-type="bullet"><list-item><p>Advanced Burkitt lymphoma</p></list-item><list-item><p>Acute lymphoblastic leukemia with a white blood cell count exceeding 100,000/&#x000b5;L or a lactate dehydrogenase level that is twice the upper limit of normal</p></list-item><list-item><p>Diffuse large B-cell lymphoma with bulky disease (&#x0003e;10 cm) and a baseline lactate dehydrogenase level greater than twice the upper limit of normal</p></list-item><list-item><p>Acute myeloid leukemia with a white blood cell count of 100,000/&#x000b5;L or more</p></list-item><list-item><p>Early-stage leukemia or Burkitt lymphoma with elevated lactate dehydrogenase</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intermediate-risk tumors
<list list-type="bullet"><list-item><p>Acute myeloid leukemia with a white blood cell count ranging from 25,000 to 100,000/&#x000b5;L</p></list-item><list-item><p>Acute lymphoblastic leukemia with a white blood cell count below 100,000/&#x000b5;L and lactate dehydrogenase levels less than twice the upper limit of normal</p></list-item><list-item><p>Diffuse large B-cell lymphoma with lactate dehydrogenase levels twice the upper limit of normal but without bulky disease</p></list-item><list-item><p>Early-stage leukemia or Burkitt lymphoma with lactate dehydrogenase levels below twice the upper limit of normal</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Low-risk tumors
<list list-type="bullet"><list-item><p>Solid cancers</p></list-item><list-item><p>Multiple myelomas</p></list-item><list-item><p>Indolent lymphomas</p></list-item><list-item><p>Chronic lymphocytic leukemia</p></list-item><list-item><p>Chronic myeloid leukemia&#x000a0;</p></list-item><list-item><p>Acute myeloid leukemia with a white blood cell count of less than 25,000/&#x000b5;L and a lactate dehydrogenase&#x000a0;elevated to less than&#x000a0;twice the upper limit of normal</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Tumors that exhibit greater sensitivity to chemotherapy agents are associated with an increased risk of tumor lysis syndrome. However, tumor lysis syndrome can also be&#x000a0;associated with administering steroids, biological immunomodulators, and monoclonal antibodies.<xref ref-type="bibr" rid="article-30680.r13">[13]</xref> Agents that are associated with the development of tumor lysis syndrome include thalidomide, bortezomib,&#x000a0;hydroxyurea,&#x000a0;paclitaxel,&#x000a0;fludarabine,&#x000a0;etoposide,&#x000a0;venetoclax,&#x000a0;rituximab,&#x000a0;obinutuzumab, and chimeric antigen receptor T-cell therapy for hematologic malignancy.<xref ref-type="bibr" rid="article-30680.r14">[14]</xref></p>
        <p>Several reports of tumor lysis syndrome occurring spontaneously before the initiation of chemotherapy have been documented in patients with non-Hodgkin lymphomas, acute leukemias, and breast cancer.<xref ref-type="bibr" rid="article-30680.r15">[15]</xref>&#x000a0;Unlike postchemotherapy tumor lysis syndrome, spontaneous tumor lysis syndrome is not associated with hyperphosphatemia. This distinction may be attributed to the high cell turnover rate in tumors, which increases uric acid levels while the tumor reutilizes the released phosphate to grow new cells. In contrast, postchemotherapy tumor lysis syndrome involves the destruction of tumor cells without the synthesis of new cells.<xref ref-type="bibr" rid="article-30680.r16">[16]</xref>&#x000a0;</p>
        <p>Certain patient factors can also predispose to an increased risk of tumor lysis syndrome.&#x000a0;Patients at higher risk for tumor lysis syndrome include those with pretreatment hyperuricemia, preexisting renal issues, oliguria, and volume depletion. Impaired renal function significantly increases tumor lysis syndrome risk, necessitating close monitoring and managing fluid status and uric acid levels before and during treatment.<xref ref-type="bibr" rid="article-30680.r12">[12]</xref><xref ref-type="bibr" rid="article-30680.r11">[11]</xref></p>
      </sec>
      <sec id="article-30680.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The exact incidence of tumor lysis syndrome remains undetermined. In a retrospective study involving 102 patients with high-grade non-Hodgkin lymphoma, the overall incidence of&#x000a0;tumor lysis syndrome was reported as 42%. However, only 6% of these cases were clinically significant.<xref ref-type="bibr" rid="article-30680.r17">[17]</xref> Susceptibility to tumor lysis syndrome does not appear to be influenced by ethnicity or sex. Analysis of the National Inpatient Sample database reveals that the malignancies most frequently associated with tumor lysis syndrome are non-Hodgkin lymphoma (30%), solid tumors (20%), acute myeloid leukemia (19%), and acute lymphoblastic leukemia (13%). The overall in-hospital mortality rate for tumor lysis syndrome is approximately 21%.<xref ref-type="bibr" rid="article-30680.r18">[18]</xref>&#x000a0;</p>
        <p>A retrospective&#x000a0;study involving 951 newly diagnosed cancer patients at a tertiary care center in the United States showed that the incidence of laboratory tumor lysis syndrome was 9.3% and clinical tumor lysis syndrome was 6.7% <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood.V120.21.238.238">(Cairo et al, Blood, 2012)</ext-link>. Hematologic cancers, particularly acute leukemia and multiple myeloma, exhibited the highest rates of tumor lysis syndrome, with laboratory tumor lysis syndrome occurring in 21.1% of cases and clinical tumor lysis syndrome in 15.1% of cases. Laboratory tumor lysis syndrome was often marked by hyperuricemia (52% of patients), whereas clinical tumor lysis syndrome commonly involved renal insufficiency (62.5%) and cardiac arrhythmias (35.9%).</p>
        <p>A study involving 788 adult and pediatric patients with acute leukemia or non-Hodgkin lymphoma in 4 European countries revealed that the incidence of tumor lysis syndrome differed between laboratory and clinical tumor lysis syndrome, with rates of 18.9% and 5%, respectively. The incidence rates for laboratory and clinical tumor lysis syndrome were 21.4% and 5.2% in acute lymphoblastic leukemia, 14.7% and 3.4% in acute myeloid leukemia, and 19.6% and 6.1% in non-Hodgkin lymphoma,&#x000a0;respectively.<xref ref-type="bibr" rid="article-30680.r19">[19]</xref></p>
      </sec>
      <sec id="article-30680.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Electrolyte Imbalances in Tumor Lysis Syndrome</bold>
</p>
        <p>Tumor lysis syndrome is caused by the massive release of intracellular ions such as potassium, phosphorus, and nucleic acids metabolized to uric acid. The main organ responsible for the excretion of these substances is the kidney. When renal compensatory mechanisms are exhausted, uric acid obstructive uropathy may develop, potentially progressing to acute kidney injury.<xref ref-type="bibr" rid="article-30680.r20">[20]</xref><xref ref-type="bibr" rid="article-30680.r21">[21]</xref></p>
        <p><bold>Hyperuricemia:&#x000a0;</bold>DNA is composed of smaller units called nucleotides, which are the building blocks of the DNA molecule. Each nucleotide consists of 3&#x000a0;main components&#x02014;a phosphate group, a sugar group, and a nitrogen base&#x000a0;(adenine, thymine, guanine, or cytosine).<bold>&#x000a0;</bold>Adenine and guanine are purines, whereas thymine and cytosine are pyrimidines. In RNA, the sugar is ribose, and the nitrogen bases include adenine, thymine, and uracil. The stepwise metabolism of adenine and guanine produces xanthine; adenine converts to hypoxanthine, whereas guanine converts to xanthine. Xanthine is further metabolized into uric acid by xanthine oxidase. Most mammals possess urate oxidase, which converts uric acid into the more soluble allantoin for renal excretion. Humans lack this enzyme. Due to the rapid turnover of tumor cells, excessive uric acid crystallizes in the renal tubules, causing obstructive uropathy and reduced glomerular filtration rate. Animal models demonstrate that urate nephropathy increases proximal and distal tubule pressure, peritubular capillary pressure, and vascular resistance. Uric acid also scavenges nitric oxide, a potent vasodilator, leading to vasoconstriction and kidney ischemia.<xref ref-type="bibr" rid="article-30680.r22">[22]</xref>&#x000a0;In addition, uric acid acts as a pro-inflammatory agent, triggering cytokine release such as tumor necrosis factor-&#x003b1;, exacerbating renal injury.<xref ref-type="bibr" rid="article-30680.r23">[23]</xref><xref ref-type="bibr" rid="article-30680.r24">[24]</xref><xref ref-type="bibr" rid="article-30680.r17">[17]</xref></p>
        <p><bold>Hyperkalemia:&#x000a0;</bold>Intracellular potassium concentrations are&#x000a0;approximately 120 to 130 meq/L. The lysis of tumor cells releases substantial amounts of potassium into the bloodstream, which is typically absorbed by the liver and skeletal muscles, with the remainder excreted through the gastrointestinal tract or kidneys. However, uric acid obstructive uropathy can impede potassium excretion, leading to potentially life-threatening hyperkalemia and the risk of cardiac arrest due to arrhythmias.</p>
        <p><bold>Hyperphosphatemia:&#x000a0;</bold>Tumor lysis syndrome&#x02013;related hyperphosphatemia is caused by phosphate release from the nucleic acids of lysed tumor cells. The phosphorus concentration in malignant cells can be up to 4 times higher than in normal cells; thus, rapid tumor cell breakdown frequently results in hyperphosphatemia. Normally, the kidneys excrete phosphorus; however, this process can be hindered by acute or chronic kidney injury. Although less common in spontaneous tumor lysis syndrome compared to chemotherapy-induced tumor lysis syndrome, hyperphosphatemia can still cause calcium chelation, resulting in hypocalcemia. Calcium-phosphorus salt deposits can form in the kidneys and soft tissues, with precipitation in the heart potentially causing cardiac arrhythmias.<xref ref-type="bibr" rid="article-30680.r25">[25]</xref><xref ref-type="bibr" rid="article-30680.r26">[26]</xref></p>
        <p><bold>Hypocalcemia:&#x000a0;</bold>Hypocalcemia in tumor lysis syndrome is mainly due to phosphorus chelation. This condition is more hazardous than hyperphosphatemia, with potential complications including arrhythmias, tetany, seizures, and death.<xref ref-type="bibr" rid="article-30680.r27">[27]</xref><xref ref-type="bibr" rid="article-30680.r28">[28]</xref>&#x000a0;Hypocalcemia may persist after normalizing phosphorus levels due to 1,25-dihydroxyvitamin D deficiency.<xref ref-type="bibr" rid="article-30680.r29">[29]</xref></p>
      </sec>
      <sec id="article-30680.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histopathological characteristics of tumor lysis syndrome include the deposition of uric acid, calcium phosphate, and xanthine crystals in the lamina of the distal kidney tubules.<xref ref-type="bibr" rid="article-30680.r30">[30]</xref>&#x000a0;In addition, uric acid crystals may accumulate within kidney tubular epithelial cells and the medulla. Low urine flow, low solubility, and high solute concentrations contribute to crystal formation. Crystal deposition in the renal pelvis, calyces, and ureter can cause inflammation, leading to urinary flow obstruction. Prolonged obstruction can result in hydroureter, hydronephrosis, and eventually acute kidney injury.</p>
      </sec>
      <sec id="article-30680.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>In the context of tumor lysis syndrome, a range of clinical signs and symptoms can emerge either before the onset of chemotherapy or, more frequently, within 72 hours after the administration of cytotoxic agents. Key areas to focus on while obtaining the medical history&#x000a0;include the timing of symptom onset relative to the malignancy, abdominal pain and distension, and urinary symptoms such as dysuria, oliguria, flank pain, and hematuria. In addition, symptoms indicative of hypocalcemia, including anorexia, vomiting, cramps, seizures, spasms, altered mental status, and tetany, should be thoroughly assessed.<xref ref-type="bibr" rid="article-30680.r31">[31]</xref></p>
        <p>Symptoms associated with hyperkalemia, such as weakness and paralysis, are also pertinent.&#x000a0;Tumor lysis syndrome may present with various other clinical manifestations, including lethargy, edema, and signs of fluid overload. Further complications may include heart failure, cardiac dysrhythmias, syncope, and, in severe cases, sudden death.</p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>The physical examination should focus on the electrolyte abnormalities associated with tumor lysis syndrome. The physical findings associated with these abnormalities include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypocalcemia
<list list-type="bullet"><list-item><p>Carpal spasm</p></list-item><list-item><p>Pedal spasm</p></list-item><list-item><p>Tetany</p></list-item><list-item><p>Chvostek sign</p></list-item><list-item><p>Trousseau sign</p></list-item><list-item><p>Wheezing associated with bronchospasm</p></list-item><list-item><p>Seizure</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Acute kidney injury and uremia from&#x000a0;hyperuricemia and obstructive uropathy
<list list-type="bullet"><list-item><p>Weakness</p></list-item><list-item><p>Lethargy</p></list-item><list-item><p>Malaise</p></list-item><list-item><p>Nausea</p></list-item><list-item><p>Vomiting</p></list-item><list-item><p>Metallic taste in the mouth</p></list-item><list-item><p>Irritability</p></list-item><list-item><p>Generalized pruritis</p></list-item><list-item><p>Rales and Ronchi from volume overload</p></list-item><list-item><p>Muffled heart sound from pericarditis secondary to uremia</p></list-item><list-item><p>Joint pain</p></list-item><list-item><p>Renal colicky pain</p></list-item><list-item><p>Calcium phosphate crystal deposits in the skin</p></list-item><list-item><p>Pruritis</p></list-item><list-item><p>Gangrene</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>The clinical presentation can be quite diverse, encompassing a range of symptoms from electrolyte disturbances to signs of fluid overload and uremia. Monitoring for these manifestations as part of the comprehensive evaluation of tumor lysis syndrome is crucial to ensure timely and appropriate management. The early identification of these clinical signs can significantly impact patient outcomes by guiding prompt intervention and treatment strategies.</p>
      </sec>
      <sec id="article-30680.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Diagnostic Evaluation</bold>
</p>
        <p>
<bold>Various studies are used in the evaluation of tumor lysis syndrome.&#x000a0;</bold>
</p>
        <p><bold>Imaging:&#x000a0;</bold>Chest radiography&#x000a0;and computed tomography (CT) imaging are essential for assessing mediastinal masses and associated pleural effusions. A CT scan or abdominal ultrasound is recommended to determine if a mass is located in the abdomen or retroperitoneum. Clinicians should exercise caution with intravenous (IV) contrast administration due to the risk of acute kidney injury associated with tumor lysis syndrome.</p>
        <p><bold>Electrocardiography:&#x000a0;</bold>Electrocardiography<bold>&#x000a0;</bold>(ECG) is essential for evaluating patients with tumor lysis syndrome to identify abnormalities related to hyperkalemia and hypocalcemia. Hyperkalemia, in particular, poses a risk of life-threatening arrhythmias, making ECG monitoring crucial for managing tumor lysis syndrome.</p>
        <p><bold>Laboratory assessments:&#x000a0;</bold>The complete blood count is used to diagnose hematologic malignancies associated with tumor lysis syndrome, with typical findings including leukocytosis, anemia, and thrombocytopenia. The comprehensive metabolic panel is used to monitor metabolic abnormalities associated with tumor lysis syndrome, such as hyperkalemia, hypocalcemia, hyperphosphatemia, and hyperuricemia. Elevated levels of blood urea nitrogen, creatinine, and lactate dehydrogenase may indicate the onset of tumor lysis syndrome and require close monitoring, ideally 2 to 3 times daily before and after the initiation of therapy. In addition, urinalysis is crucial for detecting uric acid precipitation and obstructive uropathy, with urine pH, specific gravity, and urine output assessed regularly. Urine alkalinization with sodium bicarbonate is standard practice in managing tumor lysis syndrome.</p>
        <p>
<bold>Diagnostic Criteria for&#x000a0;</bold>
<bold>Tumor Lysis Syndrome</bold>
</p>
        <p>The diagnosis of tumor lysis syndrome relies on criteria developed by Cairo and Bishop.<xref ref-type="bibr" rid="article-30680.r32">[32]</xref><xref ref-type="bibr" rid="article-30680.r7">[7]</xref><xref ref-type="bibr" rid="article-30680.r33">[33]</xref>&#x000a0;Established in 2004, the Cairo-Bishop definition outlined specific laboratory criteria for diagnosing tumor lysis syndrome at the time of presentation and within 7 days following treatment. These criteria also categorize the severity of tumor lysis syndrome, ranging from grade 0 (asymptomatic) to 5 (death), based on factors&#x000a0;such as the extent of serum creatinine elevation, the type and presence of cardiac arrhythmias, and the occurrence and severity of seizures.</p>
        <p><bold>Laboratory diagnostic criteria:&#x000a0;</bold>Tumor lysis syndrome diagnosis requires the presence of 2 or more of the following criteria within the same 24-hour period from 3 days before to 7 days after chemotherapy initiation:</p>
        <list list-type="bullet">
          <list-item>
            <p>Uric acid 25% increase from baseline or &#x02265;8.0 mg/dL</p>
          </list-item>
          <list-item>
            <p>Potassium 25% increase from baseline or&#x000a0;&#x02265;6.0 mEq/L</p>
          </list-item>
          <list-item>
            <p>Phosphorus 25% increase from baseline or&#x000a0;&#x02265;4.5 mg/dL (&#x02265;6.5 mg/dL in children)</p>
          </list-item>
          <list-item>
            <p>Calcium 25% decrease from baseline or &#x02264;7.0 mg/dL</p>
          </list-item>
        </list>
        <p><bold>Clinical diagnostic criteria:&#x000a0;</bold>Clinical tumor lysis syndrome is defined by the presence of laboratory tumor lysis syndrome plus one or more of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine greater than 1.5 times the upper limit of normal of an age-adjusted reference range</p>
          </list-item>
          <list-item>
            <p>Seizure</p>
          </list-item>
          <list-item>
            <p>Cardiac arrhythmia or sudden death</p>
          </list-item>
        </list>
        <p>In addition, other causes of acute kidney injury should be ruled out.&#x000a0;The criteria established by Cairo and Bishop have several limitations. The most significant drawback is that the definition of tumor lysis syndrome requires the initiation of chemotherapy, whereas,&#x000a0;in clinical practice, tumor lysis syndrome can develop spontaneously without initiating chemotherapy. Another limitation is the use of creatinine levels &#x0003e;1.5 times the upper limit for&#x000a0;a patient's age and gender. However, this approach is not standard, as patients with chronic kidney disease have elevated levels of creatine in the absence of acute kidney injury.<xref ref-type="bibr" rid="article-30680.r34">[34]</xref></p>
      </sec>
      <sec id="article-30680.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Prevention of Tumor Lysis Syndrome</bold>
</p>
        <p>The most important factor considered for the management of tumor lysis syndrome is the ability to prevent its development based on anticipation. The main goal of prophylaxis is to ensure sufficient urine production and to lower uric acid, potassium, and phosphate blood concentrations. The primary prophylactic strategies are IV hydration and hypouricemic agents such as allopurinol and rasburicase. Avoiding substances that can cause vasoconstriction of the renal vasculature, including but not limited to nonsteroidal anti-inflammatory drugs and iodinated contrast, is advisable.&#x000a0;Multiple clinical trials have failed to demonstrate the superiority of any particular&#x000a0;prophylactic regiment for tumor lysis syndrome. Monitoring biological values every 4 to 6 hours after starting antitumor therapy for high-risk patients, every 8 to 12 hours for those at intermediate risk, and daily for low-risk patients is recommended.<xref ref-type="bibr" rid="article-30680.r35">[35]</xref></p>
        <p>
<bold>Rapid Expansion of Intravascular Volume</bold>
</p>
        <p>Aggressive IV hydration is crucial for preventing tumor lysis syndrome in high-risk patients, aiming to improve renal perfusion, glomerular filtration, and urine output.<xref ref-type="bibr" rid="article-30680.r11">[11]</xref> For tumors with a high risk of releasing a large amount of intracellular substances after the initiation of chemotherapy, aggressive hydration should be started before the initiation of treatment. In patients with preexisting kidney or cardiac conditions, careful fluid management and monitoring are essential to avoid fluid overload, with diuretics potentially used to support urine output.</p>
        <p>Crystalloids are recommended for volume expansion to rapidly enhance the glomerular filtration rate, thereby facilitating the elimination of solutes associated with tumor lysis syndrome. IV fluid administration should commence 48 hours before&#x000a0;the initiation of chemotherapy and continue for 48 hours following chemotherapy. Adequate hydration, typically around 3 to 3.5 L/m<sup>2</sup>&#x000a0;daily or 4 to 5 L/d, may be required to achieve optimal hydration and to target a urine output of approximately 2 mL/kg/h.<xref ref-type="bibr" rid="article-30680.r36">[36]</xref><xref ref-type="bibr" rid="article-30680.r37">[37]</xref>&#x000a0;Diuretics, such as furosemide, may be used to sustain urine output but are not recommended for patients with hypovolemia or obstructive uropathy.&#x000a0;Hydration fluids should initially be free of potassium and calcium to prevent the complications of hyperkalemia and hyperphosphatemia.</p>
        <p>
<bold>Sodium Bicarbonate for Urine Alkalinization</bold>
</p>
        <p>Alkalinizing the urine increases the solubility of uric acid by about 10-fold. Urine alkalinization can be achieved by adding 40 to 50 mEq of sodium bicarbonate per liter of hydration fluid in tumor lysis syndrome. However, a potential drawback of urine alkalinization is the reduction in ionized calcium levels, which may decrease calcium-albumin binding and exacerbate hypocalcemia associated with tumor lysis syndrome, potentially resulting in arrhythmias or tetany. In addition, urine alkalinization may promote the precipitation of calcium and phosphate salts in renal tubules, worsening acute kidney injury in tumor lysis syndrome. Therefore, sodium bicarbonate should be used for urine alkalinization only in patients with metabolic acidosis when rasburicase is unavailable, and calcium levels should be monitored serially.<xref ref-type="bibr" rid="article-30680.r11">[11]</xref><xref ref-type="bibr" rid="article-30680.r38">[38]</xref></p>
        <p>
<bold>Allopurinol</bold>
</p>
        <p>Allopurinol is a structural isomer of hypoxanthine and is converted to its active metabolite, oxypurinol, by xanthine oxidase. Allopurinol competitively inhibits xanthine oxidase and blocks the conversion of xanthine to uric acid, thereby reducing the formation of uric acid and decreasing the incidence of obstructive uropathy.<xref ref-type="bibr" rid="article-30680.r39">[39]</xref> Although allopurinol effectively reduces uric acid production in tumor lysis syndrome, it does not treat hyperuricemia once it has developed.&#x000a0;Allopurinol is recommended for tumor lysis syndrome prevention, provided pretreatment uric acid levels are below 8 mg/dL (476 &#x003bc;mol/L).</p>
        <p>Adverse effects of allopurinol include skin rash, eosinophilia, and acute hepatitis, collectively known as allopurinol hypersensitivity syndrome. Clinicians should also be cautious of potential drug interactions with azathioprine, particularly in patients with solid organ transplants or autoimmune disorders.&#x000a0;Allopurinol use can lead to elevated&#x000a0;levels of xanthine in urine and serum. Xanthine has limited solubility and can crystallize in renal tubules, aggravating obstructive uropathy associated with tumor lysis syndrome.&#x000a0;</p>
        <p>Allopurinol is generally administered at a dosage of 100 mg/m&#x000b2; every 8 hours for adults, with a maximum daily dose of 800 mg, and should be adjusted for renal impairment. In children, the dosage ranges from 50 to 100 mg/m&#x000b2; every 8 hours or 10 mg/kg/d.<xref ref-type="bibr" rid="article-30680.r11">[11]</xref> IV administration can be used for those who cannot take oral medication, with a maximum dose of 600 mg/d.<xref ref-type="bibr" rid="article-30680.r40">[40]</xref> Treatment should start 24 to 48 hours before induction chemotherapy and continue for up to 7 days, depending on serum uric acid levels and other markers of tumor lysis. Screening for the <italic toggle="yes">HLA-B*58:01</italic> allele is recommended for specific high-risk populations to avoid severe cutaneous reactions, particularly in patients of Asian ancestry.<xref ref-type="bibr" rid="article-30680.r41">[41]</xref></p>
        <p>
<bold>Rasburicase</bold>
</p>
        <p>Rasburicase is recommended over allopurinol for the prevention and treatment of tumor lysis syndrome in high-risk adult and pediatric patients, particularly those with compromised renal or cardiac function. Rasburicase is a recombinant urate oxidase derived from <italic toggle="yes">Aspergillus flavus</italic> and catalyzes the conversion of uric acid to allantoin, carbon dioxide, and hydrogen peroxide. This approach contrasts with allopurinol, which inhibits uric acid formation but does not rapidly reduce serum uric acid levels.</p>
        <p>Rasburicase dosing typically starts at 0.2 mg/kg daily, with adjustments based on risk stratification and baseline uric acid levels; it can be administered intramuscularly or IV. Caution is necessary for patients with glucose-6-phosphate dehydrogenase deficiency, as hydrogen peroxide produced with rasburicase can cause severe methemoglobinemia or hemolytic anemia in these patients.<xref ref-type="bibr" rid="article-30680.r42">[42]</xref></p>
        <p>The United States Food and Drug Administration approved rasburicase in 2009.&#x000a0;In children, rasburicase has demonstrated superior efficacy compared to allopurinol. In a phase 1/2 trial involving 131 pediatric patients undergoing chemotherapy for high-risk hematologic malignancies, rasburicase effectively reduced serum uric acid levels and improved clinical outcomes without necessitating dialysis.<xref ref-type="bibr" rid="article-30680.r43">[43]</xref> A randomized trial further demonstrated rasburicase's superiority, showing more significant reductions in uric acid levels and a faster onset of action compared to allopurinol.<xref ref-type="bibr" rid="article-30680.r24">[24]</xref>&#x000a0;In adults, rasburicase has demonstrated effectiveness in managing tumor lysis syndrome with less data compared to pediatric studies. Trials have reported that rasburicase achieves faster normalization of uric acid levels and lowers the incidence of laboratory tumor lysis syndrome more effectively compared to allopurinol. However, the evidence is less robust for clinical tumor lysis syndrome outcomes and mortality benefits, partly due to study design limitations and patient heterogeneity.<xref ref-type="bibr" rid="article-30680.r44">[44]</xref></p>
        <p>
<bold>Febuxostat</bold>
</p>
        <p>Febuxostat is a newer xanthine oxidase inhibitor that is more expensive than allopurinol but does not cause the hypersensitivity reactions associated with allopurinol.&#x000a0;Febuxostat<bold>&#x000a0;</bold>requires no dose adjustment for mild-to-moderate renal impairment and has fewer drug-drug interactions.<xref ref-type="bibr" rid="article-30680.r45">[45]</xref> Febuxostat can also be used in situations where rasburicase is unavailable or contraindicated. In the clinical trial, Febuxostat for TLS Prevention in Hematologic Malignancies (FLORENCE), febuxostat demonstrated superior control of tumor lysis syndrome&#x02013;related hyperuricemia with a favorable safety profile and preservation of renal function.<xref ref-type="bibr" rid="article-30680.r46">[46]</xref> Caution is advised against concurrent use with azathioprine or mercaptopurine due to the risk of severe toxicity from increased plasma concentrations.&#x000a0;</p>
        <p>
<bold>Treatment of Tumor Lysis Syndrome</bold>
</p>
        <p>For individuals who develop tumor lysis syndrome during cancer treatment or spontaneously before chemotherapy, intensive supportive care is essential, including continuous urine output monitoring, cardiac monitoring, and regular measurements of electrolytes, creatinine, and uric acid. Management involves correcting specific electrolyte abnormalities, administering rasburicase if not previously given, hydrating to flush uric acid crystals, and considering renal replacement therapy if necessary. Early consultation with a renal specialist is recommended.<xref ref-type="bibr" rid="article-30680.r11">[11]</xref></p>
        <p>
<bold>Management of Electrolyte Abnormalities</bold>
</p>
        <p>Hyperkalemia poses a significant risk due to the potential for cardiac dysrhythmias.<bold>&#x000a0;</bold>Managing it requires&#x000a0;restricting&#x000a0;potassium and phosphate intake, frequent serum potassium monitoring, and if necessary, using potassium-lowering agents or dialysis. Calcium chloride and calcium gluconate can be administered parenterally to manage hypocalcemia. In tumor lysis syndrome, hypocalcemia often results from hyperphosphatemia, and calcium administration may exacerbate the deposition of calcium-phosphate crystals in soft tissues and kidneys, worsening acute kidney injury. Hyperphosphatemia may occasionally require hemodialysis, but management primarily involves aggressive hydration and phosphate binder therapy.</p>
        <p><bold>Hemodialysis:&#x000a0;</bold>Hemodialysis may be necessary in severe cases where potassium and phosphorus levels are excessively high due to tumor lysis syndrome&#x02013;associated acute kidney injury. Indications for renal replacement therapy include severe oliguria or anuria, fluid overload, persistent hyperkalemia, symptomatic hypocalcemia due to hyperphosphatemia, and a calcium-phosphate product &#x02265;70 mg&#x000b2;/dL&#x000b2;.<xref ref-type="bibr" rid="article-30680.r47">[47]</xref><xref ref-type="bibr" rid="article-30680.r11">[11]</xref>&#x000a0;The release of intracellular ions during tumor lysis syndrome can lead to rebound hyperkalemia or hyperphosphatemia with intermittent hemodialysis. Continuous renal replacement therapy, with a high dialysate or replacement fluid flow rate, is preferred for effective solute removal.</p>
        <p>Peritoneal dialysis is insufficient due to its lower effectiveness in clearing uric acid and phosphate. In addition, patients might experience abdominal complications related to tumors,&#x000a0;such as peritoneal carcinomatosis or compartment syndrome.&#x000a0;For life-threatening hyperkalemia, early hemodialysis is advised, whereas continuous renal replacement therapy may be the optimal approach for severe hyperphosphatemia.</p>
      </sec>
      <sec id="article-30680.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Tumor lysis syndrome should be differentiated from other clinical conditions that can cause hyperkalemia, hyperphosphatemia, and hyperuricemia.&#x000a0;The differential diagnosis of these electrolyte abnormalities includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperkalemia
<list list-type="bullet"><list-item><p>Hypocalcemia</p></list-item><list-item><p>Metabolic acidosis</p></list-item><list-item><p>Congenital adrenal hyperplasia</p></list-item><list-item><p>Toxicity from digitalis</p></list-item><list-item><p>Acute tubular&#x000a0;injury</p></list-item><list-item><p>Electrical burn</p></list-item><list-item><p>Head trauma</p></list-item><list-item><p>Rhabdomyolysis</p></list-item><list-item><p>Thermal burns</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>&#x000a0;Hyperphosphatemia
<list list-type="bullet"><list-item><p>Monoclonal gammopathy</p></list-item><list-item><p>Waldenstr&#x000f6;m macroglobulinemia</p></list-item><list-item><p>Multiple myeloma</p></list-item><list-item><p>Pseudohypoparathyroidism</p></list-item><list-item><p>Rhabdomyolysis</p></list-item><list-item><p>Vitamin D intoxication</p></list-item><list-item><p>Oral saline laxative (Phospho-soda) abuse</p></list-item><list-item><p>Pseudohyperphosphatemia</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyperuricemia
<list list-type="bullet"><list-item><p>Hyperparathyroidism</p></list-item><list-item><p>Hypothyroidism</p></list-item><list-item><p>Nephrolithiasis</p></list-item><list-item><p>Alcoholic ketoacidosis</p></list-item><list-item><p>Diabetic ketoacidosis</p></list-item><list-item><p>Gout</p></list-item><list-item><p>Pseudogout</p></list-item><list-item><p>Type 1a glycogen storage disease</p></list-item><list-item><p>Hemolytic anemia</p></list-item><list-item><p>Hodgkin lymphoma</p></list-item><list-item><p>Uric acid nephropathy</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30680.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Tumor lysis syndrome poses significant clinical risks, particularly in patients with high or intermediate risk undergoing treatments such as induction chemotherapy for acute myeloid leukemia. A retrospective study involving 772 acute myeloid leukemia patients found that tumor lysis syndrome developed in 17% of cases, with clinical tumor lysis syndrome occurring in 5% of those affected. Clinical tumor lysis syndrome significantly raised the risk of death during induction therapy, with 79% of patients with clinical tumor lysis syndrome experiencing fatal outcomes.<xref ref-type="bibr" rid="article-30680.r6">[6]</xref> The need for immediate intervention when tumor lysis syndrome is diagnosed underscores the importance of preventive strategies, particularly in high-risk populations.</p>
      </sec>
      <sec id="article-30680.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Tumor lysis syndrome can lead to severe complications, including acute kidney injury, cardiac arrhythmias, and metabolic disturbances. The rapid release of intracellular contents from lysed tumor cells results in hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, which can precipitate life-threatening conditions. The resultant electrolyte imbalances and kidney dysfunction necessitate intensive monitoring and management to prevent progression to multiple-organ failure. Clinical tumor lysis syndrome, characterized by these severe manifestations, significantly increases mortality rates and complicates treatment regimens, underscoring the critical need for early recognition and proactive prophylaxis in high-risk patients.</p>
      </sec>
      <sec id="article-30680.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Effective deterrence of tumor lysis syndrome involves proactive patient education and strategic preventive measures. Educating patients about the symptoms and risks associated with tumor lysis syndrome, including early signs such as fatigue, nausea, and changes in urination, is crucial for early detection and intervention. Preventive strategies should be tailored based on individual risk assessments and may include hydration protocols; medications, such as allopurinol or rasburicase, to manage uric acid levels; and close monitoring of electrolytes. Ensuring that patients understand the importance of adherence to these preventive measures and regular follow-up can significantly reduce the incidence and severity of tumor lysis syndrome, thereby improving overall treatment outcomes and minimizing potential complications.</p>
      </sec>
      <sec id="article-30680.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Tumor lysis syndrome is a life-threatening oncological emergency that demands prompt and precise intervention. Given the high mortality associated with improperly managed tumor lysis syndrome, identifying patients at elevated risk and initiating early preventative measures&#x000a0;are crucial. Timely recognition of the renal and metabolic disturbances characteristic of tumor lysis syndrome, along with the swift initiation of appropriate treatment, can be lifesaving. This approach necessitates the involvement of an interprofessional team comprising oncologists, nephrologists, internists, intensivists, and intensive care unit (ICU) nurses.</p>
        <p>Clinicians&#x000a0;and advanced practitioners must leverage their clinical expertise to develop and implement evidence-based treatment plans addressing the metabolic abnormalities associated with tumor lysis syndrome. ICU and oncology nurses play a critical role in treating patients with tumor lysis syndrome by providing continuous monitoring and promptly communicating any deviations in vital signs to clinicians. Pharmacists ensure accurate medication management, optimize therapeutic regimens, and mitigate potential drug interactions. Effective interprofessional communication is essential, with team members sharing vital information and collaborating to refine care plans. Ethical considerations, including respect for patient autonomy and the assurance of informed consent, are fundamental in providing comprehensive care.</p>
      </sec>
      <sec id="article-30680.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30680&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30680">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/tumor-lysis-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30680">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30680/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30680">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30680.s16">
        <title>References</title>
        <ref id="article-30680.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Barefah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wasi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ramsay</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tumour lysis syndrome in a patient with undifferentiated endometrial stromal sarcoma.</article-title>
            <source>Gynecol Oncol Rep</source>
            <year>2019</year>
            <month>May</month>
            <volume>28</volume>
            <fpage>41</fpage>
            <page-range>41-43</page-range>
            <pub-id pub-id-type="pmid">30834285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGhee-Jez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sunder</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rizk</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Spontaneous Tumor Lysis Syndrome as Presenting Sign of Metastatic Prostate Cancer.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Dec</month>
            <day>08</day>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>e3706</fpage>
            <pub-id pub-id-type="pmid">30788195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wierda</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coutre</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Furman</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Kipps</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sharman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ghia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Flinn</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ninomoto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.</article-title>
            <source>Br J Haematol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>186</volume>
            <issue>1</issue>
            <fpage>184</fpage>
            <page-range>184-188</page-range>
            <pub-id pub-id-type="pmid">30740654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Na</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>A Rare Case of Spontaneous Tumor Lysis Syndrome in Idiopathic Primary Myelofibrosis.</article-title>
            <source>Am J Case Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>03</day>
            <volume>20</volume>
            <fpage>146</fpage>
            <page-range>146-150</page-range>
            <pub-id pub-id-type="pmid">30712053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calvo Villas</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Tumour lysis syndrome.</article-title>
            <source>Med Clin (Barc)</source>
            <year>2019</year>
            <month>May</month>
            <day>17</day>
            <volume>152</volume>
            <issue>10</issue>
            <fpage>397</fpage>
            <page-range>397-404</page-range>
            <pub-id pub-id-type="pmid">30612747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montesinos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lorenzo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Sirvent</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ort&#x000ed;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Algarra</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moscard&#x000f3;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de la Rubia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jarque</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sanz</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.</article-title>
            <source>Haematologica</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-74</page-range>
            <pub-id pub-id-type="pmid">18166787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Killeen</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Tumor Lysis Syndrome.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>143</volume>
            <issue>3</issue>
            <fpage>386</fpage>
            <page-range>386-393</page-range>
            <pub-id pub-id-type="pmid">30499695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalemkerian</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Darwish</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Varterasian</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Tumor lysis syndrome in small cell carcinoma and other solid tumors.</article-title>
            <source>Am J Med</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>103</volume>
            <issue>5</issue>
            <fpage>363</fpage>
            <page-range>363-7</page-range>
            <pub-id pub-id-type="pmid">9375703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drakos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bar-Ziv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Catane</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature.</article-title>
            <source>Am J Clin Oncol</source>
            <year>1994</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>502</fpage>
            <page-range>502-5</page-range>
            <pub-id pub-id-type="pmid">7977169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baeksgaard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-92</page-range>
            <pub-id pub-id-type="pmid">12655435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Younes</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cairo</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Jun</month>
            <day>01</day>
            <volume>26</volume>
            <issue>16</issue>
            <fpage>2767</fpage>
            <page-range>2767-78</page-range>
            <pub-id pub-id-type="pmid">18509186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cairo</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Younes</surname>
                <given-names>A</given-names>
              </name>
              <collab>TLS Expert Panel</collab>
            </person-group>
            <article-title>Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.</article-title>
            <source>Br J Haematol</source>
            <year>2010</year>
            <month>May</month>
            <volume>149</volume>
            <issue>4</issue>
            <fpage>578</fpage>
            <page-range>578-86</page-range>
            <pub-id pub-id-type="pmid">20331465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malik</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Abubakar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dexamethasone-induced tumor lysis syndrome in high-grade non-Hodgkin's lymphoma.</article-title>
            <source>South Med J</source>
            <year>1994</year>
            <month>Mar</month>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>409</fpage>
            <page-range>409-11</page-range>
            <pub-id pub-id-type="pmid">8134869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maude</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Laetsch</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Buechner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rives</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bader</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verneris</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Stefanski</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Qayed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Moerloose</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hiramatsu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schlis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Nemecek</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Yanik</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baruchel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boissel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mechinaud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Balduzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krueger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>June</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taran</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pulsipher</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>378</volume>
            <issue>5</issue>
            <fpage>439</fpage>
            <page-range>439-448</page-range>
            <pub-id pub-id-type="pmid">29385370</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jasek</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Acute spontaneous tumor lysis syndrome.</article-title>
            <source>Am J Hematol</source>
            <year>1994</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-31</page-range>
            <pub-id pub-id-type="pmid">8092128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kjellstrand</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cambell</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>von Hartitzsch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buselmeier</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Hyperuricemic acute renal failure.</article-title>
            <source>Arch Intern Med</source>
            <year>1974</year>
            <month>Mar</month>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>349</fpage>
            <page-range>349-59</page-range>
            <pub-id pub-id-type="pmid">4283735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hande</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Garrow</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma.</article-title>
            <source>Am J Med</source>
            <year>1993</year>
            <month>Feb</month>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-9</page-range>
            <pub-id pub-id-type="pmid">8430709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stephanos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pediatric Oncologic Emergencies.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>527</fpage>
            <page-range>527-535</page-range>
            <pub-id pub-id-type="pmid">30037439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Annemans</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moeremans</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lamotte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia Conde</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Myint</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pieters</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uyttebroeck</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries.</article-title>
            <source>Leuk Lymphoma</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-83</page-range>
            <pub-id pub-id-type="pmid">12691145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hochberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cairo</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Tumor lysis syndrome: current perspective.</article-title>
            <source>Haematologica</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-13</page-range>
            <pub-id pub-id-type="pmid">18166779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Nabey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chaba</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lenglin&#x000e9;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Darmon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zafrani</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy.</article-title>
            <source>Ann Intensive Care</source>
            <year>2022</year>
            <month>Feb</month>
            <day>15</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <pub-id pub-id-type="pmid">35166948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>3553</fpage>
            <page-range>3553-62</page-range>
            <pub-id pub-id-type="pmid">16251237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cirillo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gersch</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Scherer</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gesualdo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sautin</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Ketohexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>545</fpage>
            <page-range>545-53</page-range>
            <pub-id pub-id-type="pmid">19158351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldman</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Holcenberg</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Finklestein</surname>
                <given-names>JZ</given-names>
              </name>
              <name>
                <surname>Hutchinson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kreissman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Tou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cairo</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.</article-title>
            <source>Blood</source>
            <year>2001</year>
            <month>May</month>
            <day>15</day>
            <volume>97</volume>
            <issue>10</issue>
            <fpage>2998</fpage>
            <page-range>2998-3003</page-range>
            <pub-id pub-id-type="pmid">11342423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boles</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Dutel</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Briere</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mialon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Robasckiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Briere</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia.</article-title>
            <source>Cancer</source>
            <year>1984</year>
            <month>Jun</month>
            <day>01</day>
            <volume>53</volume>
            <issue>11</issue>
            <fpage>2425</fpage>
            <page-range>2425-9</page-range>
            <pub-id pub-id-type="pmid">6585264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanfer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chatelet</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Extreme hyperphosphataemia causing acute anuric nephrocalcinosis in lymphosarcoma.</article-title>
            <source>Br Med J</source>
            <year>1979</year>
            <month>May</month>
            <day>19</day>
            <volume>1</volume>
            <issue>6174</issue>
            <fpage>1320</fpage>
            <page-range>1320-1</page-range>
            <pub-id pub-id-type="pmid">582154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>The tumor lysis syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>May</month>
            <day>12</day>
            <volume>364</volume>
            <issue>19</issue>
            <fpage>1844</fpage>
            <page-range>1844-54</page-range>
            <pub-id pub-id-type="pmid">21561350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Schafer</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Shoback</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <chapter-title>Hypocalcemia: Diagnosis and Treatment</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2016</year>
            <month>1</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">25905251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunlay</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Camp</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Allon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fanti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Malluche</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Llach</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Calcitriol in prolonged hypocalcemia due to the tumor lysis syndrome.</article-title>
            <source>Ann Intern Med</source>
            <year>1989</year>
            <month>Jan</month>
            <day>15</day>
            <volume>110</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-4</page-range>
            <pub-id pub-id-type="pmid">2909207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Lingegowda</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Van</surname>
                <given-names>QC</given-names>
              </name>
              <name>
                <surname>Dass</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ejaz</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>10</issue>
            <fpage>2960</fpage>
            <page-range>2960-4</page-range>
            <pub-id pub-id-type="pmid">19581334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mughal</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Ejaz</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Foringer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Coiffier</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>164</fpage>
            <page-range>164-76</page-range>
            <pub-id pub-id-type="pmid">20031331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cairo</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tumour lysis syndrome: new therapeutic strategies and classification.</article-title>
            <source>Br J Haematol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-11</page-range>
            <pub-id pub-id-type="pmid">15384972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Belay</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yirdaw</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Enawgaw</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Tumor Lysis Syndrome in Patients with Hematological Malignancies.</article-title>
            <source>J Oncol</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>9684909</fpage>
            <pub-id pub-id-type="pmid">29230244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alhamid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sabbagh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alsarraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lerma</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caza</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Workeneh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barrientos</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Jhaveri</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Pitfalls of Current Diagnostic Criteria of Tumor Lysis Syndrome.</article-title>
            <source>Kidney Blood Press Res</source>
            <year>2024</year>
            <month>Mar</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">38471470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupu&#x00219;oru</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ailinc&#x00103;i</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fr&#x00103;&#x0021b;il&#x00103;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ungureanu</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Andronesi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lupu&#x00219;oru</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>V&#x00103;c&#x00103;roiu</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sinescu</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology.</article-title>
            <source>Biomedicines</source>
            <year>2022</year>
            <month>Apr</month>
            <day>28</day>
            <volume>10</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">35625753</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Amsberg</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>[Oncological emergencies in chemotherapy : Febrile neutropenia, tumor lysis syndrome, and extravasation].</article-title>
            <source>Urologe A</source>
            <year>2018</year>
            <month>May</month>
            <volume>57</volume>
            <issue>5</issue>
            <fpage>552</fpage>
            <page-range>552-557</page-range>
            <pub-id pub-id-type="pmid">29508029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>PZ</given-names>
              </name>
              <name>
                <surname>Hamlin</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Tumor Lysis Syndrome: A Unique Solute Disturbance.</article-title>
            <source>Nurs Clin North Am</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>309</fpage>
            <page-range>309-320</page-range>
            <pub-id pub-id-type="pmid">28478879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conger</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Intrarenal dynamics in the pathogenesis and prevention of acute urate nephropathy.</article-title>
            <source>J Clin Invest</source>
            <year>1977</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>786</fpage>
            <page-range>786-93</page-range>
            <pub-id pub-id-type="pmid">16037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>KRAKOFF</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>MEYER</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.</article-title>
            <source>JAMA</source>
            <year>1965</year>
            <month>Jul</month>
            <day>05</day>
            <volume>193</volume>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">14297704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smalley</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Guaspari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haase-Statz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Cederberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hohneker</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Allopurinol: intravenous use for prevention and treatment of hyperuricemia.</article-title>
            <source>J Clin Oncol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>1758</fpage>
            <page-range>1758-63</page-range>
            <pub-id pub-id-type="pmid">10764437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ko</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Weng</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chuang</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>CY</given-names>
              </name>
              <collab>Taiwan Allopurinol-SCAR Consortium</collab>
            </person-group>
            <article-title>Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.</article-title>
            <source>BMJ</source>
            <year>2015</year>
            <month>Sep</month>
            <day>23</day>
            <volume>351</volume>
            <fpage>h4848</fpage>
            <pub-id pub-id-type="pmid">26399967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaikh</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Marini</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Hough</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Perissinotti</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Rational use of rasburicase for the treatment and management of tumor lysis syndrome.</article-title>
            <source>J Oncol Pharm Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>176</fpage>
            <page-range>176-184</page-range>
            <pub-id pub-id-type="pmid">28077046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pui</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Wiley</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Leverger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Camitta</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hastings</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Blaney</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Relling</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Reaman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2001</year>
            <month>Feb</month>
            <day>01</day>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>697</fpage>
            <page-range>697-704</page-range>
            <pub-id pub-id-type="pmid">11157020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Maziarz</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Wetzler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matous</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Luger</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dey</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Schiller</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abboud</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Krishnamurthy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laadem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Seiter</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Sep</month>
            <day>20</day>
            <volume>28</volume>
            <issue>27</issue>
            <fpage>4207</fpage>
            <page-range>4207-13</page-range>
            <pub-id pub-id-type="pmid">20713865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayer</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Khosravan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vernillet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Joseph-Ridge</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mulford</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.</article-title>
            <source>Am J Ther</source>
            <year>2005</year>
            <season>Jan-Feb</season>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-34</page-range>
            <pub-id pub-id-type="pmid">15662289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ribera</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Federico</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aurer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Borsaru</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pristupa</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Bosi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grosicki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glushko</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Ristic</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jakucs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Montesinos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rego</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scartoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Capriati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maggi</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Simonelli</surname>
                <given-names>C</given-names>
              </name>
              <collab>FLORENCE Study Group</collab>
            </person-group>
            <article-title>FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.</article-title>
            <source>Ann Oncol</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>10</issue>
            <fpage>2155</fpage>
            <page-range>2155-61</page-range>
            <pub-id pub-id-type="pmid">26216382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30680.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Will</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>S</given-names>
              </name>
              <collab>British Committee for Standards in Haematology</collab>
            </person-group>
            <article-title>Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology.</article-title>
            <source>Br J Haematol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>169</volume>
            <issue>5</issue>
            <fpage>661</fpage>
            <page-range>661-71</page-range>
            <pub-id pub-id-type="pmid">25876990</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
